Share this article
Share this article
NAPLES, Fla., May 12, 2021 /PRNewswire/ Enveric Biosciences (NASDAQ: ENVB) ( Enveric or the Company ), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, announced today that it has appointed Arash Asher, M.D., Director of Cancer Rehabilitation and Survivorship at the Cedars-Sinai Cancer Center, to the Company s Scientific Advisory Board. We believe that Dr. Asher s decision to join Enveric s Scientific Advisory Board gives the Company a significant advantage given his extensive time and expertise at Cedars-Sinai, said David Johnson, Chairman and CEO, Enveric Biosciences. Our mission at Enveric is focused on improving cancer patients quality of life through leveraging the power of cannabinoid medicines. Dr. Asher s deep knowledge of chemotherapy-induced peripheral neuropathy and more should help us achieve this goal of bringing safe, effective care to can